42.33 0.00 (0.00%)
After hours: 7:55PM EDT
|Bid||0.00 x 1200|
|Ask||0.00 x 900|
|Day's Range||42.09 - 42.77|
|52 Week Range||32.32 - 42.77|
|PE Ratio (TTM)||11.31|
|Forward Dividend & Yield||1.36 (3.23%)|
|1y Target Est||N/A|
Amgen’s (AMGN) product portfolio includes the blockbuster drugs Prolia, Enbrel, Neulasta, Xgeva, Aranesp, Sensipar/Mimpara, Kyprolis, and Epogen. Blockbuster drug Neulasta (pegfilgrastim) reported a 1% rise in revenue to $1.10 billion during the second quarter compared to ~$1.09 billion in the second quarter of 2017.
Major pharmaceutical companies are partying like it’s 2001. U.S. drugmakers including Pfizer Inc., Eli Lilly & Co., and Merck & Co. are seeing their share prices balloon to the highest levels in more than 16 years as investors rotate in after second-quarter results proved stronger than expected. Impressive earnings paired with waning concerns about potential Trump administration actions on drug pricing could be helping to draw generalist investors in a bit of a “catch up trade,” according to Credit Suisse analyst Vamil Divan.
Array BioPharma (ARRY) is developing a number of combination therapies with its investigational MEK inhibitor binimetinib with PD-1/PD-L1 checkpoint inhibitors. The company is conducting the trials in collaboration with Bristol-Myers Squibb (BMY), Pfizer (PFE), and Merck (MRK). During its fourth-quarter and full-fiscal 2018 earnings release on August 14, Array Biopharma provided updates on these trials.
Mylan (MYL) made a downward revision to its fiscal 2018 guidance during its second-quarter earnings release on August 8. A major factor driving down the company’s performance was lower North America sales due to volume declines in the company’s existing products. Due to the impact of “turbulence in the U.S. and the disturbing trends regarding access to complex products,” Mylan lowered its fiscal 2018 guidance during its second-quarter earnings release on August 8.
Mylan (MYL) ended the second quarter with cash and cash equivalents of $330.2 million. This compared to the net cash provided by operating activities of $1.02 billion available to the company by the end of the fiscal second quarter of 2017. For the six months ended June 30, Mylan’s adjusted free cash flows were $1.3 billion, up ~22% YoY (year-over-year).
On August 16, Teva announced positive top-line data for its NGF-inhibitor Fasinumab, which is being developed in collaboration with Regeneron. Teva’s stock price rise was also boosted by the FDA approval of Teva’s generic version of EpiPen, which we covered in FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%. Teva also has Fremanezumab in its product pipeline, which is expected to be a key growth driver for the company and is being developed for the treatment of migraines.
Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products, including eye care products, medical esthetics products, dermatology products, neuroscience products, and urology products.
The Dow Jones industrial average led a light yet broad rally in stocks today. Chip stocks weighed on the leading index of growth companies. Pfizer is gaining more traction.
Pfizer Inc's ( PFE) stock has surged higher by more than 16% in 2018. Now shares may be due to fall by about 10% based on technical analysis. The technical chart shows Pfizer's stock breaking out at the start of July when it increased above technical resistance at $37 and has risen by more than 13% since. Now shares are bumping up against a resistance level around $42, that goes back for nearly two decades to late 2001, and that may prove difficult for the stock to rise above.
Spark Therapeutics, Rite Aid, and Alnylam Pharmaceuticals shares have dropped recently, but that doesn't necessarily make all three stocks worth buying.
Mylan’s (MYL) epinephrine auto-injector EpiPen is approved as the first line of treatment for life-threatening allergic reaction anaphylaxis. During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.
Mylan NV’s EpiPen is still hard to find at many pharmacies, three months after U.S. authorities declared that the lifesaving allergy device was in shortage, a survey by Wells Fargo & Co. showed. The finding comes a day after Teva Pharmaceutical Industries Ltd. gained Food and Drug Administration approval to sell a generic version of Mylan’s epinephrine autoinjector. Wells Fargo analysts reached out to 53 pharmacies across the country on Thursday and found that 66 percent were out of stock of Mylan’s EpiPens, not including EpiPen Jr., analyst Davis Maris said in a note Friday.
Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.
The life-saving allergy medicine has had manufacturing disruptions since May, but allergy sufferers and caregivers may find it especially hard to find now, as parents try to stock up to send their kids back to school.
Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.
Today, Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr. The epinephrine autoinjector is used to treat allergic reactions, including life-threatening condition of anaphylaxis. The company received FDA approval for the use of the product in adults as well as children weighing more than 33 pounds. In 2016, Teva’s generic version of EpiPen was unable to secure FDA approval.
Jim Cramer answers callers' questions about how to diversify their portfolios, including which tech stocks to keep and which to throw out.